PTC Therapeutics
PTCT
178 hedge funds and large institutions have $3B invested in PTC Therapeutics in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 65 reducing their positions, and 26 closing their positions.
8% more capital invested
Capital invested by funds: $2.78B → $3B (+$226M)
0.98% more ownership
Funds ownership: 105.64% → 106.62% (+0.98%)
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
8% less call options, than puts
Call options by funds: $1.86M | Put options by funds: $2.03M
2% less funds holding
Funds holding: 182 → 178 (-4)
17% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 65
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$90M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$12.5M |
| 3 |
Goldman Sachs
New York
|
+$11.4M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$9.49M |
| 5 |
Morgan Stanley
New York
|
+$6.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$64.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$23.4M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$8.04M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.29M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$5.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWS
201
Glassman Wealth Services
Vienna,
Virginia
| – | -$498 | -13 | -72% |
|
202
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$306 | -8 | -44% |
|
|
IRC
203
Investors Research Corp
Atlanta,
Georgia
| – | +$153 | +4 | New |
|
|
SCA
204
Snowden Capital Advisors
New York
| – | +$651 | +17 | New |
|
PTCT Hedge Fund Activity: Q4 2021 in Review
178 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2021, worth a combined $3B — up 8.1% from $2.78B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PTCT and 24 opened new positions — a net loss of 2 holders — while 65 trimmed existing stakes and 54 added.
The largest buyer was Bank of America, adding an estimated $90M. The largest seller was Armistice Capital, cutting an estimated $64.3M.
- 178 institutional investors held PTC Therapeutics (PTCT) as of Q4 2021, down from 182 in Q3 2021.
- Funds reported $3B of PTC Therapeutics stock for Q4 2021, up 8.1% quarter-over-quarter.
- 24 funds opened new PTC Therapeutics positions in Q4 2021 and 26 closed out, a net change of -2 holders.
- The largest PTC Therapeutics buyer in Q4 2021 was Bank of America, an estimated $90M added.
- The largest PTC Therapeutics seller in Q4 2021 was Armistice Capital, an estimated $64.3M sold.
Based on aggregated 13F filings for Q4 2021.